FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

NCT03319459 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Gastric Cancer
Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
EGFR Positive Solid Tumor
Advanced Solid Tumors
HER2-positive Breast Cancer
Hepatocellular Carcinoma
Non Small Cell Lung Cancer
Renal Cell Carcinoma
Pancreatic Cancer
Melanoma

Interventions

DRUG: FATE-NK100
DRUG: Cetuximab
DRUG: Trastuzumab

Sponsor

Fate Therapeutics